UNSPSC 51384624: Bendazac sodium

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4SW243Q44Z, chemically known as sodium, ((1-(phenylmethyl)-1h-indazol-3-yl)oxy)acetate but more generally known as bendazac sodium, which bears US NIH Compound Identifier 31020. European Medicines Agency schedules Bendazac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00698MIG.

Most nations, for tariff and trade purposes, schedule bendazac sodium under HS 29339990. As of Q4 2014, BENDAZAC SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)CN2C3CCCCC3C(N2)OCC(=O)[O-].[NA+].

UNSPSC 51384624 Bendazac sodium is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local procurement activity under this code shows minimal alignment with that product. The three most recent opportunities posted under this code are for naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative exploring direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). None of these solicitations specifically name bendazac sodium as a procurement target. The code appears to serve as a catch-all classification for pharmaceutical procurement activity when more specific commodity codes do not apply, rather than representing demand for bendazac sodium itself.

Activity is geographically dispersed across Texas, Florida, and the Upper Midwest, with the most recent and substantive solicitation being MMCAP's RFP (posted January 20, 2026; due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota, Oregon, and other MMCAP member jurisdictions. Issuing bodies span state agencies (Texas HHS, Minnesota Department of Administration), counties (Seminole County), and cooperative purchasing organizations. The MMCAP solicitation is the most material opportunity, with product delivery effective July 1, 2026, requiring vendors to maintain relationships with three authorized wholesalers, demonstrate cGMP and DSCSA compliance, carry $5 million commercial general liability insurance, and accept a 3 percent administrative fee on all purchases. The Seminole County IFB seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries beginning in 2023 (note: posting dates appear inconsistent in the source), while the Texas HHS RFI is exploratory market intelligence gathering with no immediate procurement commitment. Bendazac sodium has no evident recent activity under this code.